Wet Age-Related Macular Degeneration Market Analysis by 2034: Statistics, Growth, Market Size, Trends, and Companies by DelveInsight

(Albany, USA) DelveInsight's "Wet Age-Related Macular Degeneration Market Insights, Epidemiology, and Market Forecast-2034" report offers a comprehensive analysis of Wet Age-Related Macular Degeneration, covering historical and projected epidemiology along with market trends across the United States, the EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan. It presents insights into current treatment practices, pipeline therapies, market share by therapy, and the current and forecasted market size from 2020 to 2034 for the seven major markets. The report also examines treatment algorithms, key market drivers and barriers, and unmet medical needs, identifying prime opportunities and evaluating the growth potential of the Wet Age-Related Macular Degeneration market.

Discover which therapies are expected to grab the Wet Age-Related Macular Degeneration Market Share @ Wet Age-Related Macular Degeneration Market Outlook - https://www.delveinsight.com/report-store/wet-age-related-macular-degeneration-wet-amd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Key Takeaways from the Wet Age-Related Macular Degeneration Market Report
• In April 2025, Kodiak Sciences Inc. announced phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal Tarcocimab Tedromer and Tabirafusp Tedromer Compared With Intravitreal Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD)
• In the assessment done by DelveInsight, the estimated total diagnosed prevalent cases of Age-Related Macular Degeneration (AMD) in the 7MM were nearly 40 million in 2023.
• The highest total diagnosed prevalent cases of Age-Related Macular Degeneration (AMD) were accounted by the US in 2023 (~14 million), which are expected to show a rise in the future.
• Among the European countries, Germany had the highest diagnosed prevalent cases of Age-Related Macular Degeneration (AMD) with ~6 million cases in 2023. On the other hand, Spain had the lowest prevalent population (~2 million cases).
• Japan had nearly 8 million total diagnosed prevalent cases of Age-Related Macular Degeneration (AMD) in 2023, accounting for approximately 21% in 7MM.
• Based on age-specific segmentation, the people in the age group of 70-79 were affected the most by Wet Age-Related Macular Degeneration (Wet AMD) in the US, accounting for approximately 406 thousand cases in 2023.
• The DelveInsight analysis indicates that in Japan, there are more number of cases of people with Dry AMD than people with Wet AMD, with approximately 90% of total cases and 10% of cases in 2023.
• Among the European countries, Germany had the highest diagnosed prevalent cases of Wet AMD with ~595 thousand cases, followed by France, which had prevalent population of ~389 thousand in 2023. On the other hand, Spain had the lowest prevalent population (~160 thousand cases).
• Japan had ~840 thousand total diagnosed prevalent cases of Wet Age-Related Macular Degeneration (Wet AMD) in 2023, accounting for approximately 21% in 7MM.
• In 2023, in the US, the age-specific diagnosed prevalent cases of Wet AMD were highest for age group 70-79 (~407 thousand), followed by 60-69 (~393 thousand), =80 (~304 thousand), and 50-59 (~252 thousand).
• The increase in Wet Age-Related Macular Degeneration Market Size is a direct consequence of the increasing patient population and anticipated launch of emerging therapies in the 7MM.
• As per DelveInsight analysis, the Wet Age-Related Macular Degeneration Market is anticipated to witness growth at a considerable CAGR.
• The leading Wet Age-Related Macular Degeneration Companies such as Opthea Limited, Outlook Therapeutics, Kodiak Sciences, Regenxbio, Dobecure, Gemini Therapeutics, Huabo Biopharm, Isarna Therapeutics, IVERIC bio (formerly Ophthotech Corporation), Ribomic, Curacle, Bio-Thera Solutions, AngioLab Inc, Alkahest, Tyrogenex, Iconic Therapeutics, AiViva BioPharma, Boehringer Ingelheim, RemeGen, and others.
• Promising Wet Age-Related Macular Degeneration Pipeline Therapies such as RGX-314, Tarcocimab tedromer, Aflibercept, KSI-301, Eyp-1901, ALK4290, and others.

Wet Age-Related Macular Degeneration Epidemiology Segmentation in the 7MM
The epidemiology section of Wet Age-Related Macular Degeneration offers insights into both historical and current patient populations, as well as forecasted trends across seven major countries. This section aids in understanding the factors behind present and projected trends through analysis of various studies and input from key opinion leaders. Additionally, this portion of the market report provides information on the diagnosed patient pool, trends, and underlying assumptions.
• Total Prevalent Cases of Age-Related Macular Degeneration (AMD)
• Diagnosed Prevalent Cases of Age-Related Macular Degeneration (AMD)
• Type-Specific Diagnosed Prevalent Cases of Age-Related Macular Degeneration (AMD)
• Total Age-Specific Cases of Wet Age-Related Macular Degeneration (Wet AMD)

Download the report to understand which factors are driving Wet Age-Related Macular Degeneration Epidemiology trends @ Wet Age-Related Macular Degeneration Prevalence - https://www.delveinsight.com/sample-request/wet-age-related-macular-degeneration-wet-amd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Wet Age-Related Macular Degeneration Marketed Drugs
• BEOVU (Brolucizumab): Novartis
BEOVU (Brolucizumab), developed by Novartis, is a potent anti-VEGF treatment used for Wet Age-Related Macular Degeneration (Wet-AMD). It works by inhibiting vascular endothelial growth factor, reducing abnormal blood vessel growth and fluid leakage in the retina. BEOVU offers a longer dosing interval, allowing up to 12-week dosing schedules.

• EYLEA (aflibercept): Regeneron Pharmaceuticals
EYLEA, developed by Regeneron, is used to treat wet age-related macular degeneration (wet-AMD), diabetic eye disease, and other retinal issues. The drug, aflibercept, is an injectable treatment that slows vision loss by blocking abnormal blood vessel growth in the eye. EYLEA works as a soluble decoy receptor, inhibiting VEGF-A and PlGF to prevent abnormal blood vessel formation. The standard dosage is 2 mg every 4 weeks for the first 3 months, then every 8 weeks. Regeneron is currently testing less frequent dosing and higher doses in ongoing phase III trials.

• VABYSMO (faricimab): Roche/ Genentech, Inc.
VABYSMO (faricimab) is the first bispecific antibody designed for the eye. It targets and inhibits two signalling pathways linked to a number of vision-threatening retinal conditions by neutralizing angiopoietin-2 (Ang-2) and vascular endothelial growth factor-A (VEGF-A). Ang-2 and VEGF-A contribute to vision loss by destabilizing blood vessels, causing new leaky blood vessels to form and increasing inflammation. By blocking both pathways involving Ang-2 and VEGF-A, VABYSMO is designed to stabilize blood vessels.

Stay ahead in the Wet Age-Related Macular Degeneration Therapeutics Market with DelveInsight's Strategic Report @ Wet Age-Related Macular Degeneration Market Outlook - https://www.delveinsight.com/sample-request/wet-age-related-macular-degeneration-wet-amd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Wet Age-Related Macular Degeneration Emerging Drugs
• OPT-302: Opthea Limited
OPT-302 (sVEGFR-3) is the first 'Trap' inhibitor of VEGF-C and VEGF-D designed specifically for the eye. OPT-302 blocks the two members of the VEGF family which cause blood vessels to grow and leak. Aberrant blood vessel growth and vascular leakage are hallmarks of several eye diseases, including wet AMD and DME. In combination with anti-VEGF-A therapies, OPT-302 completely shuts-down VEGFR-2 and VEGFR-3 activity and targets mechanisms of resistance and suboptimal clinical response to existing therapies.

• KSI-501: Kodiak Sciences Inc.
KSI-501 is a novel anti-VEGF biologic designed to rapidly inhibit VEGF and provide extended durability of action to reduce the burden of frequent anti-VEGF injections. Delivering potent and sustained VEGF inhibition enables patient compliance, results in long-term efficacy, and improves visual acuity outcomes.

Wet Age-Related Macular Degeneration Market Outlook
In 2023, the US had the largest Wet Age-Related Macular Degeneration (Wet AMD) market in the 7MM at USD 2,599 million, projected to grow at a 6.6% CAGR by 2034. The US also reported the highest AMD prevalence, with about 18 million cases. Approved treatments include EYLEA, LUCENTIS, BEOVU, and AVASTIN, with EYLEA leading the market at USD 4,276 million. Growth is driven by aging populations, innovation, and screening, though costs, access, and treatment burden remain barriers. Japan's market was USD 1,163 million, expected to grow 2.6% CAGR. Emerging therapy OPT-302 (Sozinibercept) is in Phase III trials and may significantly reduce disease burden.

Wet Age-Related Macular Degeneration (wet AMD) is a degenerative eye disorder marked by the formation of abnormal blood vessels beneath the retina, often leading to significant vision loss. The primary goal of treatment is to control symptoms, slow disease progression, and maintain vision. The standard therapy for wet AMD is anti-vascular endothelial growth factor (anti-VEGF) treatment, which blocks VEGF-a protein responsible for abnormal blood vessel growth. Drugs such as ranibizumab (LUCENTIS), aflibercept (EYLEA), and brolucizumab (BEOVU) are delivered via intravitreal injections to reduce fluid leakage and vessel formation, helping to stabilize or improve vision in many patients.

The wet AMD market is fueled by factors like the increasing prevalence of the disease due to global population aging, greater awareness, earlier diagnosis, and advancements in treatment, including anti-VEGF and emerging gene therapies. Strong research pipelines, rising healthcare spending, and supportive government programs also support growth. Nonetheless, challenges remain, including high treatment costs, limited access in low-income areas, the burden of frequent injections, and issues with sustaining long-term results and patient compliance. Furthermore, competition among available therapies and the complexities of developing retinal disease treatments can restrict market expansion.

Learn more about the FDA-approved drugs for Wet Age-Related Macular Degeneration @ Drugs for Wet Age-Related Macular Degeneration Treatment - https://www.delveinsight.com/sample-request/wet-age-related-macular-degeneration-wet-amd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Wet Age-Related Macular Degeneration Drugs Uptake
The drug section of the Wet Age-Related Macular Degeneration market report offers an in-depth review of both approved treatments and late-stage pipeline therapies for the disease. It covers key aspects such as clinical trial data, mechanisms of action, partnerships and collaborations, regulatory approvals, patents, and the pros and cons of each drug, along with the latest updates, news, and press releases pertaining to Wet Age-Related Macular Degeneration.
Major Wet Age-Related Macular Degeneration Companies are Opthea Limited (ASX: OPT), Outlook Therapeutics (NASDAQ: OTLK), Kodiak Sciences (NASDAQ: KOD), Regenxbio (NASDAQ: RGNX), Dobecure (Private), Gemini Therapeutics (NASDAQ: GMTX), Huabo Biopharm (Private), Isarna Therapeutics (Private), IVERIC bio (NASDAQ: ISEE), Ribomic (TYO: 4591), Curacle (KOSDAQ: 301300), Bio-Thera Solutions (SHA: 688177), AngioLab Inc. (KOSDAQ: 251280), Alkahest (Acquired by Grifols - BME: GRF), Tyrogenex (Private), Iconic Therapeutics (Private), AiViva BioPharma (Private), Boehringer Ingelheim (Private), RemeGen (HKEX: 9995, SHA: 688331), and others

Scope of the Wet Age-Related Macular Degeneration Market Report
• Coverage- 7MM
• Study Period- 2020-2034
• Wet Age-Related Macular Degeneration Companies- Opthea Limited, Outlook Therapeutics, Kodiak Sciences, Regenxbio, Dobecure, Gemini Therapeutics, Huabo Biopharm, Isarna Therapeutics, IVERIC bio (formerly Ophthotech Corporation), Ribomic, Curacle, Bio-Thera Solutions, AngioLab Inc, Alkahest, Tyrogenex, Iconic Therapeutics, AiViva BioPharma, Boehringer Ingelheim, RemeGen, and others.
• Wet Age-Related Macular Degeneration Pipeline Therapies- RGX-314, Tarcocimab tedromer, Aflibercept, KSI-301, Eyp-1901, ALK4290, and others.
• Wet Age-Related Macular Degeneration Market Dynamics: Wet Age-Related Macular Degeneration Market Drivers and Barriers
• Wet Age-Related Macular Degeneration Market Access and Reimbursement, Unmet Needs and Future Perspectives

Discover more about Wet Age-Related Macular Degeneration Drugs in development @ Wet Age-Related Macular Degeneration Clinical Trials Assessment and FDA Approvals - https://www.delveinsight.com/sample-request/wet-age-related-macular-degeneration-wet-amd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679

About DelveInsight
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

This release was published on openPR.